Buprenorphine/naloxone becomes a Type 2 medication
Jul 18, 2019
On July 15, 2019, buprenorphine/naloxone products changed from a Type 1 to a Type 2 medication. A TPP secure 2-part form and registration with TPP Alberta are no longer required in order to prescribe buprenorphine/naloxone.
Although registration with TPP Alberta is no longer required to prescribe buprenorphine/naloxone, nurse practitioners in Alberta must complete a CARNA recognized prescribing course in opioid use disorder and follow the Prescribing Standards for Nurse Practitioners.
Changing buprenorphine/naloxone to a Type 2 medication facilitates the prescribing of buprenorphine/naloxone for Albertans with opioid use disorder. Buprenorphine/Naloxone is as effective as methadone for treatment of opioid use disorder but with an improved safety profile. CARNA supports the principles of harm reduction and this change by TPP Alberta.